$ARWR insider trading
Over the last 12 months, Arrowhead Pharmaceuticals insiders reported no purchases and 19 sales totaling $37.5M across SEC Form 4 filings. 79% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $37.5M 19 events
- Events · 12m
- 19 Form 4 filings, grouped
- Insiders · 12m
- 9 distinct reporters
- 10b5-1 share
- 79% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Hamilton James CChief Medical Officer · O | ▼ Sale | 10,000 | $75 | $750K | -4.2% | plan |
| Apr 22, 2026 | Apel Daniel JosephChief Financial Officer · O | ▼ Sale | 13,095 | $71.35 | $934K | -7.4% | plan · 3 tranches |
| Mar 5, 2026 | Hamilton James CChief Medical Officer · O | ▼ Sale | 10,000 | $64.19 | $642K | -4% | plan |
| Jan 5, 2026 | Hamilton James CChief Medical Officer · O | ▼ Sale | 40,164 | $63.11 | $2.5M | -18.9% | plan · 7 tranches |
| Jan 5, 2026 | O'Brien PatrickCOO · O | ▼ Sale | 49,493 | $63.11 | $3.1M | -9.4% | plan · 12 tranches |
| Jan 2, 2026 | Anzalone Christopher RichardChief Executive Officer · O·D | ▼ Sale | 13,187 | $66.1 | $872K | -0.3% | plan · 2 tranches |
| Dec 29, 2025 | Anzalone Christopher RichardChief Executive Officer · O·D | ▼ Sale | 51,726 | $69.13 | $3.6M | -1.3% | plan · 2 tranches |
| Dec 26, 2025 | Ferrari MauroD | ▼ Sale | 7,530 | $70 | $527K | -9.8% | plan |
| Dec 22, 2025 | Anzalone Christopher RichardChief Executive Officer · O·D | ▼ Sale | 26,031 | $68.04 | $1.8M | -0.7% | plan · 5 tranches |
| Dec 19, 2025 | Vakiener VictoriaD | ▼ Sale | 10,040 | $67.68 | $679K | -21.9% | plan · 3 tranches |
| Dec 19, 2025 | Waddill William D.D | ▼ Sale | 8,367 | $67.65 | $566K | -12.9% | plan · 3 tranches |
| Dec 19, 2025 | OLUKOTUN ADEOYE YD | ▼ Sale | 10,000 | $67.66 | $677K | -22.9% | plan · 3 tranches |
| Dec 17, 2025 | Anzalone Christopher RichardChief Executive Officer · O·D | ▼ Sale | 85,000 | $64.04 | $5.4M | -2.2% | 4 tranches |
| Dec 16, 2025 | Anzalone Christopher RichardChief Executive Officer · O·D | ▼ Sale | 184,298 | $67 | $12.3M | -4.5% | 12 tranches |
| Dec 5, 2025 | PERRY MICHAEL SD | ▼ Sale | 16,250 | $61.03 | $992K | -12.4% | — |
| Nov 28, 2025 | Ferrari MauroD | ▼ Sale | 8,750 | $56.39 | $493K | -11.3% | — |
| Oct 1, 2025 | Hamilton James CChief Medical Officer · O | ▼ Sale | 20,000 | $35 | $700K | -8.6% | plan |
| Sep 12, 2025 | Hamilton James CChief Medical Officer · O | ▼ Sale | 15,000 | $30 | $450K | -6.1% | plan |
| Sep 2, 2025 | Hamilton James CChief Medical Officer · O | ▼ Sale | 15,000 | $25 | $375K | -5.7% | plan |
| Aug 15, 2025 | Hamilton James CChief Medical Officer · O | ▼ Sale | 10,000 | $20 | $200K | -3.7% | plan · 2 tranches |
Every $ARWR filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Arrowhead Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ARWR feed.